Risk minimisation educational material for sarilumab (Kevzara) -

Risk minimisation educational material for sarilumab (Kevzara)
Information type: Safety alerts
Source: Genzyme Therapeutics
Specialities: Musculo-skeletal disorders
Summary
Patients should receive a patient alert card before starting therapy. This advises people of their treatment and warns about the possible increased risk of serious infections, neutropenia and gastrointestinal perforation, and when to seek immediate medical attention.
UKMi comment
Sanofi Genzyme is required to distribute copies of the regulatory authority approved risk minimisation educational material for Kevzara® (sarilumab) as a condition of the marketing authorisation.
Related links: Patient alert card